2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3143 Epigenetic resistance to emergency myelopoiesis drives enhanced self-renewal of hematopoietic stem cells lacking Tet2

James Swann, Jun Hou Fung, PhD2, Oakley Olson3, Ruiyuan Zhang4, Lucas Ruffinatto5, Melissa A. Proven6, Emmanuelle Passegue, PhD7
1 Columbia University, New York, New York, United States
2 Columbia University, New York, New York, United States
3 Columbia University, New York, New York, United States
4 Columbia University, New York, New York, United States
5 Columbia University, New York, New York, United States
6 Columbia University, New York, New York, United States
7 Columbia University, New York, New York, United States

Hematopoietic stem cells (HSC) acquire somatic mutations in epigenetic regulators like Tet2, endowing them with competitive advantages over wild type cells, thus resulting in clonal hematopoiesis (CH). CH is a major risk factor for development of leukemia, but rates of progression vary among individuals, suggesting environmental factors interact with somatic mutations to drive clonal selection. Inflammatory and regenerative stimuli cause activation of distinct cellular and molecular mechanisms in HSCs, collectively termed emergency myelopoiesis (EM) pathways, but the role of EM pathways in CH progression is underexplored.

To investigate how EM pathway activation might affect clonal structure in Tet2-mutant hematopoiesis, we used the CARLIN mouse model that contains CRISPR/Cas9-rearranged endogenous barcodes. We found that EM pathway activation induced by the cytotoxic drug 5-fluorouracil (5FU) did not alter Tet2-mutant HSC clone sizes but selected for Tet2-mutant HSC clones enriched for stemness genes and with lower expression of myeloid differentiation programs. Functionally, 5FU-exposed Tet2-mutant HSCs maintained a more quiescent state and had restricted differentiation compared to 5FU-exposed wild type control HSCs. Single-cell RNA and ATAC sequencing revealed greater predicted JunB activity and lesser Myc induction in 5FU-exposed Tet2-mutant HSCs compared to controls. However, after generating a novel mouse line lacking both Tet2 and JunB in the hematopoietic compartment, we found JunB was not responsible for the abnormal self-renewal phenotype of Tet2-mutant HSCs after 5FU exposure, nor for competitive advantage of Tet2-mutant cells upon transplant. Instead, we found a key role for Myc activity in controlling these responses. Using CUT&RUN, we observed a marked impairment in Myc chromatin occupancy in Tet2-mutant HSCs following 5FU treatment, which prevented normal metabolic activation and subsequent myeloid differentiation. Moreover, analysis of Tet2-mutant CARLIN clones and re-analysis of published human CH data showed that suppressed Myc activity was a key attribute of successful clones that maintained a self-renewing state. Taken together, these results identify a specific molecular mechanism of suppressed Myc activity that permits Tet2-mutant HSC clones to maintain an abnormal self-renewing state in the face of inflammatory and regenerative stress, thus promoting CH progression. Our findings further establish EM pathway activation as one of the key drivers of somatic evolution in CH.

James Swann: No relevant conflicts of interest to declare.